



## PRESS RELEASE

### MICROCELLULOSE WEIßENBORN SITE IN GERMANY RECEIVES EXCiPACT GMP AND GDP CERTIFICATION AS PHARMACEUTICAL EXCIPIENT SUPPLIERS

**Brussels, 5 February 2019**

EXCiPACT asbl is pleased to announce that the **Microcellulose Weißenborn GmbH & Co KG** (member of JRS Group) **site in Weißenborn/Erzgebirge, Germany** has recently been awarded an EXCiPACT GMP/GDP Certificate from **DQS**, one of EXCiPACT's internationally-recognised Certification Bodies. The Certificate demonstrates that this site manufactures and distributes pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) Certification Standards. Its scope covers manufacturing and distribution of pharmaceutical excipients based on organic fibres.

Both **DQS** and their auditors had to undergo a rigorous assessment process in order to be EXCiPACT Registered. Both have satisfied the additional EXCiPACT competency requirements set out in the EXCiPACT annex to the ISO/IEC 17021-1:2015 standard. In addition, their auditors have successfully completed the 2-day EXCiPACT Auditor Training Course and post-course written examination followed by an independently witnessed audit to verify that their competency is to the required standard. **DQS** also had to have their auditor's report verified by an independent certification board prior to issuing the certificate.

For full details of all sites that have been EXCiPACT certified to date in 16 Countries (Canada, China, Belgium, France, Germany, India, Israel, Italy, Japan, Saudi Arabia, Singapore, Spain, Switzerland, The Netherlands, UK and USA), see <http://www.excipact.org/certificate-holders.html>.

EU and U.S. pharmaceutical regulations require drug manufacturers to conduct either their own or commission third-party physical audits of all their starting material suppliers to demonstrate GMP and/or GDP compliance thus increasing the audit burden. However, using GMP and GDP standards designed specifically for pharmaceutical excipients, the independent, high quality EXCiPACT Certification Scheme helps pharmaceutical excipient users and their suppliers to demonstrate their commitment to GMP/GDP, to reduce their audit burden, to save costs and to assure quality.

#### Notes for the Editor

EXCiPACT asbl provides management oversight for the high quality, voluntary international EXCiPACT Certification Scheme that provides for independent 3rd party GMP and/or GDP certification of manufacturers, suppliers and distributors of pharmaceutical excipients worldwide. The Scheme ensures patient safety through supplier quality while minimising the overall costs for assessing the excipient supply chain. It has been operational since early 2013 since when there has been considerable interest among pharmaceutical excipient suppliers, customers and regulators. For further information see [www.excipact.org](http://www.excipact.org) or contact [info@excipact.org](mailto:info@excipact.org)